DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peritoneal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peritoneal cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Peritoneal Cancer Pipeline Outlook

Key Takeaways from the Peritoneal cancer Pipeline Report

• In May 2025, Corcept Therapeutics announced a Phase 2 study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
• In May 2025, Imunon conducted a phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
• In May 2025, Merck Sharp & Dohme LLC organized a study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
• DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Peritoneal Cancer treatment.
• The leading Peritoneal Cancer Companies such as Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma and others.
• Promising Peritoneal Cancer Pipeline Therapies such as Avastin, Docetaxel, BIBF 1120, epothilone b, Trabectedin, DOXIL, Dexamethasone, Bevacizumab, CP-547,632, Paclitaxel, and others.

Stay ahead with the most recent pipeline outlook for Peritoneal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peritoneal Cancer Treatment Drugs

Peritoneal Cancer Emerging Drugs Profile

• Masitinib: AB Science

Masitinib is an orally administered tyrosine kinase inhibitor. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib’s mechanism of action in peritoneal cancer involves inhibiting tumor growth by targeting specific kinases like KIT and PDGFR, crucial for cancer progression, without causing general toxicity. Currently, the drug is in Phase III stage of its clinical trial for the treatment of peritoneal cancer.

• Azenosertib: Zentalis Pharmaceuticals

Azenosertib is a potentially first-in-class and best-in-class small molecule Wee1 inhibitor in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors, and we have designed Azenosertib to have advantages over other investigational therapies, including superior selectivity and pharmacokinetic properties. Currently, the drug is in Phase II stage of its clinical trial for the treatment of peritoneal cancer.

• IMGN151: ImmunoGen

IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). IMGN151 comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRα, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. Currently, the drug is in Phase I stage of its clinical trial for the treatment of peritoneal cancer.

The Peritoneal Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Peritoneal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.
• Peritoneal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peritoneal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peritoneal Cancer market

Explore groundbreaking therapies and clinical trials in the Peritoneal Cancer Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Peritoneal Cancer Drugs

Peritoneal Cancer Companies

Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma and others

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Peritoneal Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Peritoneal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Peritoneal Cancer Market Drivers and Barriers

Scope of the Peritoneal Cancer Pipeline Report

• Coverage- Global
• Peritoneal Cancer Companies- Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma and others.
• Peritoneal Cancer Pipeline Therapies- Avastin, Docetaxel, BIBF 1120, epothilone b, Trabectedin, DOXIL, Dexamethasone, Bevacizumab, CP-547,632, Paclitaxel, and others.
• Peritoneal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peritoneal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peritoneal Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Peritoneal Cancer Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Peritoneal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peritoneal cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Masitinib: AB Science
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Azenosertib: Zentalis Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IMGN151: ImmunoGen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Peritoneal cancer Key Companies
21. Peritoneal cancer Key Products
22. Peritoneal cancer- Unmet Needs
23. Peritoneal cancer- Market Drivers and Barriers
24. Peritoneal cancer- Future Perspectives and Conclusion
25. Peritoneal cancer Analyst Views
26. Peritoneal cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight